---
title: "Fortress Biotech Pref Share FBIOP 9.375 15/12/22 | 8-K: FY2025 Q2 Revenue: USD 16.41 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253097869.md"
datetime: "2025-08-14T20:19:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253097869.md)
  - [en](https://longbridge.com/en/news/253097869.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253097869.md)
---

# Fortress Biotech Pref Share FBIOP 9.375 15/12/22 | 8-K: FY2025 Q2 Revenue: USD 16.41 M

Revenue: As of FY2025 Q2, the actual value is USD 16.41 M.

EPS: As of FY2025 Q2, the actual value is USD 0.45.

### Cash and Cash Equivalents

-   As of June 30, 2025, Fortress Biotech’s consolidated cash and cash equivalents totaled $74.4 million, an increase of $17.1 million from $57.3 million as of December 31, 2024.

### Segment Revenue

-   Journey Medical’s net product revenues for the second quarter ended June 30, 2025, were $15.0 million, compared to $14.9 million for the same period in 2024.
-   Fortress Biotech’s consolidated net revenue totaled $16.4 million for the second quarter ended June 30, 2025, compared to $14.9 million for the second quarter of 2024.

### Operational Metrics

-   Consolidated research and development expenses were $8.1 million for the second quarter ended June 30, 2025, compared to $12.7 million for the same period in 2024.
-   Consolidated selling, general and administrative costs were $38.8 million for the second quarter ended June 30, 2025, compared to $20.8 million for the same period in 2024.
-   Consolidated net income attributable to common stockholders was $13.4 million, or $0.50 per share basic, and $0.45 per share diluted, for the second quarter ended June 30, 2025, compared to a net loss of - $13.3 million, or - $0.73 per share basic and diluted, for the second quarter ended June 30, 2024.

### Outlook / Guidance

-   Fortress Biotech anticipates the PDUFA goal date for CUTX-101 on September 30, 2025, and the potential issuance of a Priority Review Voucher upon approval.
-   The company plans to advance MB-101, in combination with MB-108, as a potential treatment option for high-grade gliomas.
-   Journey Medical continues to expand payer coverage for Emrosi™, now reaching 65% of U.S. commercial lives.

### Related Stocks

- [FBIOP.US](https://longbridge.com/en/quote/FBIOP.US.md)

## Related News & Research

- [Kingdom Holding Announces Latest Development On Its Investment In SpaceX](https://longbridge.com/en/news/289680648.md)
- [MaxLinear (MXL) Stock Valuation Looks Stretched Versus Popular Fair Value Estimate](https://longbridge.com/en/news/289680170.md)
- [Mark Zuckerberg's Net Worth Crashes $31 Billion This Year, But Analysts Still Bullish on Meta](https://longbridge.com/en/news/289670977.md)
- [Regeneron (REGN) Stock Valuation After WHO Ebola Trial Backing And Expanding R&D Collaborations](https://longbridge.com/en/news/289661069.md)
- [Should Alcoa’s Quebec Wharf 17 Logistics Upgrade Prompt Reassessment From Alcoa (AA) Investors?](https://longbridge.com/en/news/289661460.md)